Gilead Sciences Inc News - GILD

Get an advanced news scanner tailored to your needs by ADVFN

Gilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2024 financial results and guidance will be released on Thursday...

FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six

– Efficacy and Safety Profile of Once-Daily Vemlidy Demonstrated in Children Six Years of Age (Weighing at Least 25kg) and Older – Gilead...

Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program

-- Gilead Granted Exclusive License to Xilio’s Tumor-Activated IL-12 Program, Including XTX301, a...

Gilead Sciences Announces Completion of Acquisition of CymaBay

Acquisition Reinforces Gilead’s Leadership in Developing Innovative Therapies For Challenging Liver Diseases Gilead Sciences, Inc. (Nasdaq: GILD...

Center for Disease Analysis Foundation Announces First Round of Grantees for the CDAF-Relink Grant

The Center for Disease Analysis Foundation (CDA Foundation) is thrilled to announce the first-round recipients of the CDAF-Relink grant to...

Form SC TO-T/A - Tender offer statement by Third Party: [Amend]

Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender Offer

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of...

Biktarvy® Demonstrates High Rates of Viral Suppression in People With HIV and Comorbidities

– New Data Evaluating the Efficacy and Safety Profile of Biktarvy for the Treatment of People with HIV and Hepatitis B or Tuberculosis will be...

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

– Week 24 Results Support Continued Development as a Potential Long-Acting Oral Combination Treatment Option in Virologically Suppressed People...

👍️0

jondoeuk 3 weeks ago

Interesting (preclinical) data from another company. It summarises two distinct phenotypes of cells within the product (they are manufacturing), each of which plays a different role in responding to cancer cells. Each cell population were separated based on whether they produced CD4 on their surface (CD4+ vs. CD4-). Cells negative for CD4 (CD4-) were better able to kill target cancer cells via the CD19 CAR. In contrast, CD4+ cells proliferated faster in response to CD19+ cancer cells. The two groups of cells also produced a different cytokine response in response to CAR activation.

👍️0

jondoeuk 1 month ago

Kite Analyst & Investor Event https://s29.q4cdn.com/585078350/files/doc_events/2024/Mar/14/gild_kite-analyst-investor-event-14-march-2024.pdf

👍️0

jondoeuk 1 month ago

I found the poster, but nothing on the design of the CARs, data on ex vivo expansion, or the percentage of CD62L+ NKTs https://www.jci.org/articles/view/83476 https://journals.aai.org/jimmunol/article/201/7/2141/107140/IL-21-Selectively-Protects-CD62L-NKT-Cells-and

👍️0

jondoeuk 1 month ago

Some more https://www.abstractsonline.com/pp8/#!/20272/presentation/10568

👍️0

Monksdream 3 months ago

GILD new 52 week high

👍️0

jondoeuk 4 months ago

Preclinical API-192 data https://ash.confex.com/ash/2023/webprogram/Paper181271.html

It is a first-in-class OTS CAR-NKT cell therapy that expresses dual CARs (targeting CD19 and CD20) and sIL-15. API-192 is the first development candidate out of a '21 collaboration and license agreement with Kite.

👍️0

jondoeuk 5 months ago

Another next-gen collab https://www.businesswire.com/news/home/20231030344859/en/Kite-and-Epic-Bio-Announce-Collaboration-to-Develop-New-Therapies-for-Cancer

There have been a number of these over the years, but nothing seems to come of them

👍️0

jondoeuk 5 months ago

The ACLX partnership looks like it could be be a gold mine. The ASH data completely dooms TSVT https://ash.confex.com/ash/2023/webprogram/Paper189761.html

If Breyanzi can't take share from Yescarta, Abecma doesn't stand a chance. They made sure to point out how Carvytki is giving some Parkinsonian-like events where they have not seen it (yet). Carvykti vs ddBCMA is going to be a battle down the road.

👍️0

Greedy G 7 months ago

~bought 9/22 $80 calls .08c

👍️0

jondoeuk 12 months ago

Q1 results https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171789595

👍️0

DewDiligence 1 year ago

Why is an oral prodrug of Remdesivir anything to get excited about?

👍️0

jondoeuk 1 year ago

Obeldesivir (an oral prodrug of remdesivir) https://news.yahoo.com/gilead-details-promising-early-covid-223448308.html

👍️0

jondoeuk 1 year ago

Kite just released ZUMA-7 results for 2L https://www.businesswire.com/news/home/20230320005701/en/Kite%E2%80%99s-Yescarta%C2%AE-CAR-T-cell-Therapy-Demonstrates-a-Statistically-Significant-Improvement-in-Overall-Survival-for-Initial-Treatment-of-RelapsedRefractory-Large-B-cell-Lymphoma

What's big is that the trial reached five year maturity instead of just the number of deaths. Looking at it, more than 210 of the 359 (58%) are still alive at five years compared to 43% in ZUMA-1 (3L+). Sure, these were healthier patients, but the CR rate was more double (65% vs. 32%) against the standard of care. So, treatment works better in healthier patients. ZUMA-23 in 1L (against R-CHOP) is ongoing.

The next question is whether treating healthier patients with multiple myeloma (if they can resolve supply issues with auto) can (significantly) improve PFS.

👍️0

fink 1 year ago

Christmas sell off over, last day to lock in any paper tax loss. LOL

Who’s losing money here?

I think we start the trend back up into Q1

👍️0

fink 1 year ago

It wants $90.
I got a sell order in @88, but think it will continue up.
Gilead is moving away from HIV and more into this cancer thingy.

That’s not enough in my mind to justify the rise. But I do think as World central banks default and the Fed starts to absorb these other world bank’s debt on foreign currency collapse, private money has to go somewhere safe. Pharma has always been recession proof. Gilead was a great stock to load. Like LNG was 7 years ago. No end is sight there too

Gilead still needs revenue from its new cancer avenues. HIV, they own and always will. Just already built into the $60 stock price

👍️0

PennyPusher786 1 year ago

It's at a 3 year high

👍️0

fung_derf 1 year ago

Very funny that you posted this to me. I couldn't recall, but knew there were a couple of you who followed me over here. It has had a pretty nice month.

I_luv_cydy

Re: fung_derf post# 3875

Tuesday, May 19, 2020 2:32:23 PM

Post#
3878
of 4839
Fung: Why do you suppose GILD keeps dropping? I'm a shareholder for a while.

👍️0

fink 1 year ago

Nice to see GILD over $80

Wonder if I should trim some? It’s been eating chit pie for some time.
Still don’t see why the spike.

👍️0

jondoeuk 1 year ago

Kite and Refuge Biotechnologies Announce Exclusive License Agreement for Investigational Gene Expression Platform for Blood Cancers https://www.businesswire.com/news/home/20221020005633/en/Kite-and-Refuge-Biotechnologies-Announce-Exclusive-License-Agreement-for-Investigational-Gene-Expression-Platform-for-Blood-Cancers

Some preclinical data from Refuge Bio https://jitc.bmj.com/content/8/Suppl_3/A86.2 https://jitc.bmj.com/content/9/Suppl_2/A162 https://jitc.bmj.com/content/9/Suppl_2/A164 https://jitc.bmj.com/content/8/Suppl_3/A458.2

👍️0

Zeppo 2 years ago

Gilead has underperformed for so long, given the size of the company as well, that I could encourage Bill Ackman to make a run at it.

👍️0

DewDiligence 2 years ago

GILD details why the purportedly-positive Trodelvy data from Mar 2022 weren’t:

https://www.businesswire.com/news/home/20220603005437/en The study met its primary endpoint of progression-free survival (PFS) with a statistically significant and clinically meaningful 34% reduction in the risk of disease progression or death (median PFS 5.5 vs. 4 months; HR: 0.66; 95% CI: 0.53-0.83; P<0.0003). The first interim analysis of the key secondary endpoint of overall survival (OS) demonstrated a trend in improvement. In this context, a “trend in improvement” means non-statsig. OS could conceivably turn statsig in a later data cut, but that’s pretty unlikely.

The viewpoint in #msg-158260565 (from 2020) has not changed.

👍️0

mick 2 years ago

Gilead Sciences Inc (GILD)
59.77 ? -1.79 (-2.91%)
Volume: 10,483,423 @04/29/22 7:42:23 PM EDT
Bid Ask Day's Range
59.53 60.0 59.27 - 62.06
GILD Detailed Quote

👍️0

jondoeuk 2 years ago

ZUMA-11. Improved CAR-T responses with 4-1BB agonist utomilumab added to axi-cel. The cells were more of central and effector phenotype. No (S)AE concerns.

👍️0

jondoeuk 2 years ago

Link to the audio recording https://investors.gilead.com/events/event-details/gilead-sciences-oncology-deep-dive

👍️0

jondoeuk 2 years ago

Oncology Deep Dive https://investors.gilead.com/static-files/332d0c81-fa18-44fa-82d3-babf96ca12d0

https://endpts.com/with-more-than-30-oncology-partners-gilead-lays-out-its-2030-vision-of-20-new-approvals/

👍️0

jondoeuk 2 years ago

ZUMA-12 https://www.nature.com/articles/s41591-022-01731-4

The CR rate was higher than standard frontline chemo, with just a single treatment vs. six cycles over about four months.

No reason to think long-term curve won't flatten like ZUMA-1 (which was post ~two years).

PDUFA date (for 2nd line) is April 1.

👍️0

mick 2 years ago

GILD News: Gilead price target slashed at Barclays following new Trodelvy data 03/10/2022 05:38:07 AM
GILD News: Current Report Filing (8-k) 03/07/2022 03:31:07 AM
GILD News: Phase 3 TROPiCS-02 Study Met the Primary Endpoint of Progression-Free Survival in Late-Line HR+/HER2- Metastatic Breast Cancer 03/07/2022 03:30:00 AM
GILD News: Robert W. Baird Sticks to Their Hold Rating for Gilead Sciences (GILD) 03/03/2022 12:10:51 AM
GILD News: Jefferies Thinks Gilead Sciences’ Stock is Going to Recover 03/02/2022 03:35:55 AM

👍️0

mick 2 years ago

Gilead Sciences Inc (GILD)
58.39 ? 0.47 (0.81%)
Volume: 13,007,627 @03/11/22 7:41:31 PM EST
Bid Ask Day's Range
58.2 58.4 57.955 - 59.185
GILD Detailed Quote

👍️0

mick 2 years ago

Gilead Sciences Inc (GILD)
61.33 ? 0.22 (0.36%)
Volume: 9,751,206 @02/15/22 4:17:32 PM EST
Bid Ask Day's Range
61.15 61.33 60.97 - 61.515
GILD Detailed Quote

👍️0

mick 2 years ago

Gilead Sciences Inc (GILD)
63.9 ? -1.49 (-2.28%)
Volume: 12,392,843 @02/04/22 7:58:42 PM EST
Bid Ask Day's Range
63.8 64.0 63.8722 - 65.61
GILD Detailed Quote

👍️0

DewDiligence 2 years ago

GILD owes ViiV* $1.25B+_3% royalty on_US Biktarvy sales, as a result of a patent settlement:

https://www.gsk.com/en-gb/media/press-releases/gsk-announces-settlement-between-viiv-healthcare-and-gilead-sciences/

The 3% royalty is a pretty big deal since Biktarvy’s had annualized US sales of $8.4B(!) in 4Q21.

* ViiV is a JV comprised of: GSK (76.5%); PFE (13.5%); and Shionogi (10%).

👍️0

DewDiligence 2 years ago

GILD 4Q21 results…

PR:
https://investors.gilead.com/static-files/107ab0e3-735c-4760-882f-c3647ea97ce2

CC slides:
https://investors.gilead.com/static-files/afa262c5-7eed-4944-81f5-3c2d09489d1b

👍️0

mick 2 years ago

https://www.otcmarkets.com/stock/GILD

👍️0

DewDiligence 2 years ago

GILD vs BMY in LBCL CAR-T—who has the edge?

https://www.fiercepharma.com/pharma/bristol-myers-squibb-breyanzi-gilead-yescarta-lock-horns-car-t-therapy-earlier-lymphoma

Both Yescarta and Breyanzi are poised to take share from stemcell transplants.

👍️0

mick 2 years ago

https://www.otcmarkets.com/stock/GILD

👍️0

dhbuzz 2 years ago

GILD and MTNB have been working on ORAL remdesivir ,results to date look outstanding ,if this is green lighted by FDA,should really give GILD a SP jump as well as MTNB

GLTA

👍️0

DewDiligence 2 years ago

VIR/GILD start phase-2 trial testing quadruple regimen of VIR-2218; GS-9688; Opdivo; and Vemlidy (TAF) in (both nuc-suppressed and viremic) HBV patients:

https://finance.yahoo.com/news/vir-biotechnology-announces-initiation-phase-133000267.html

I’m not sure why it took almost a year for this trial to begin enrolling patients—the PR announcing the collaboration was issued on 1/12/21.

Please see #msg-160854272 for background.

👍️0

Michel 2 years ago

I Agree: https://www.griproom.com/fun/pfizers-covid-pill-might-not-be-as-great-as-theyre-saying

Brilacidina y Remdesivir

👍️0

Ultimate01 2 years ago

Showtime this week! Brilacidin is a BEAST. Remdesivir needs Brilicidin to remain relevant and in the market but Brilacidin does not need Remdesivir. Gilead has the opportunity to remain relevant and go down in history as the company that helped end the pandemic, or the company that missed the greatest opportunity.

👍️0

mick 2 years ago

Gilead Sciences Inc (GILD)
66.68 ? 0.21 (0.32%)
Volume: 6,519,261 @11/05/21 7:59:38 PM EDT
Bid Ask Day's Range
66.16 66.68 65.76 - 66.87
GILD Detailed Quote

👍️0

mick 2 years ago

i think so they got ah good pipeline though

👍️0

Michel 2 years ago

http://www.ipharminc.com/press-release/2020/9/15/laboratory-testing-of-brilacidin-for-covid-19-in-combination-with-remdesivir-reduces-viral-load-by-nearly-100-percent

http://www.ipharminc.com/press-release/2021/10/25/innovation-pharmaceuticals-covid-19-clinical-trial-topline-results-anticipated-to-be-reported-the-week-of-november-8th

Be careful with this, the clock runs fast, pay attention to the week of November 8 or even earlier

👍️0

slimhere 2 years ago

Mick, I think we are the only ones watching GILD on iHub, whatever.

I bought more, could have bought better, but what the hay, I feel the sell off was uncalled for on dividend alone, we beat on earning as well as revenues, I believe investors wanted to know why Trodelvy results weren't part of the call, O'Day gave his reasons, he had to be political correct, plus what he said may very well be true; however, the FDA was never efficient but with Covid, they were working remote, hell, they hardly worked when they were at the office, plus, a lot of resources went to studying Covid itself as well as vaccination drugs. That's my nickel take on what's going on, here's what O'Day said.

Gilead CEO Dan O'Day says the delay isn't concerning, and is common in studies that require a certain number of patients to have their cancer worsen before data are analyzed. "Nothing has changed concerning our confidence" in the study's outcome, O'Day says. The delay could be a good sign, assuming Trodelvy patients are taking longer than expected to have their disease worsen. But RBC warns it could also be the control chemotherapy group causing the delay. Trodelvy had 3Q sales of $101M, in line with analyst projections. Trodelvy's sales are projected to be $689M in 2022, and to reach $2.1B in annual sales in 2025.

Gilead Sciences Inc (GILD)
65.92 ? -0.85 (-1.27%)
Volume: 5,723,324 @10/28/21 4:55:20 PM EDT
Bid Ask Day's Range
65.8 65.95 66.67 - 67.66
GILD Detailed Quote

👍️0

slimhere 2 years ago

5PM, we'll see how close you are, I'm hoping you're a tab low.

👍️0

mick 3 years ago

$gild should be over $80 to $100 imho

Gilead Sciences Inc (GILD)
68.25 ? 0.11 (0.16%)
Volume: 4,259,030 @10/08/21 6:48:20 PM EDT
Bid Ask Day's Range
67.8 68.25 67.82 - 68.41
GILD Detailed Quote

👍️0

mick 3 years ago

$gild should be over $80 to $100 imho

Gilead Sciences Inc (GILD)
68.25 ? 0.11 (0.16%)
Volume: 4,259,030 @10/08/21 6:48:20 PM EDT
Bid Ask Day's Range
67.8 68.25 67.82 - 68.41
GILD Detailed Quote

👍️0

dhbuzz 3 years ago

https://www.msn.com/en-us/health/medical/protein-found-on-infected-cells-protects-virus-from-immune-system-remdesivir-helps-prevent-hospitalization/ar-AAOSTU8?ocid=msedgdhp&pc=U531

👍️0

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Gilead Sciences Inc (GILD)

Get an advanced news scanner tailored to your needs by ADVFN

GILD News

Gilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024

FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six

Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program

Gilead Sciences Announces Completion of Acquisition of CymaBay

Center for Disease Analysis Foundation Announces First Round of Grantees for the CDAF-Relink Grant

Form SC TO-T/A - Tender offer statement by Third Party: [Amend]

Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender Offer

Biktarvy® Demonstrates High Rates of Viral Suppression in People With HIV and Comorbidities

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers

New Real-World Data Further Support the Use of Veklury® (Remdesivir) for People Hospitalized With COVID-19

Gilead’s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

GILD Discussion

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Gilead Sciences Inc (GILD) News

Gilead Sciences Inc (GILD)

Get an advanced news scanner tailored to your needs by ADVFN

GILD News

Gilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024

FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six

Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program

Gilead Sciences Announces Completion of Acquisition of CymaBay

Center for Disease Analysis Foundation Announces First Round of Grantees for the CDAF-Relink Grant

Form SC TO-T/A - Tender offer statement by Third Party: [Amend]

Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender Offer

Biktarvy® Demonstrates High Rates of Viral Suppression in People With HIV and Comorbidities

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers

New Real-World Data Further Support the Use of Veklury® (Remdesivir) for People Hospitalized With COVID-19

Gilead’s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

GILD Discussion

Your Recent History

Company

Business

Popular

Get The App